Alnylam Pharmaceuticals vs Neurocrine Biosciences
Alnylam Pharmaceuticals is the larger business, with $3.71bn of revenue in fiscal 2025 against $2.86bn for Neurocrine Biosciences (1.3 times as much). Alnylam Pharmaceuticals grew faster (65.2% against 21.4%). Neurocrine Biosciences kept more of each dollar of sales as profit: a net margin of 16.7% against 8.4%. Neurocrine Biosciences carries less debt relative to equity (0.0% against 127.7%).
| Latest fiscal year | Alnylam PharmaceuticalsALNY, 2025 | Neurocrine BiosciencesNBIX, 2025 |
|---|---|---|
| Revenue | $3.71bn | $2.86bn |
| Revenue growth | 65.2% | 21.4% |
| Net income | $314m | $479m |
| Operating margin | 13.5% | 21.6% |
| Net margin | 8.4% | 16.7% |
| Return on equity | 73.3% | 16.4% |
| Free cash flow | $465m | $749m |
| Cash | $1.66bn | $713m |
| Total debt | $1.01bn | $0 |
| Debt to equity | 127.7% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $168m |
| Employees | 2,500 | 1,800 |
| Market value | $21.46bn | $16.93bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 33 (Weak) | 61 (Moderate) |
| Insider trades, 12 months | 0 buys, 279 sales | 0 buys, 40 sales |